Ending diagnostic odysseys and inspiring hope
For patients with rare and complex conditions, physicians and other healthcare professionals need trusted answers. Our tests are developed through leading-edge research and unmatched clinical expertise, creating a diagnostics ecosystem that delivers insights that set a new standard in diagnostic care.
Successful patient outcomes are our priority, and we work with hospitals and physicians around the world to elevate diagnostic excellence everywhere. As part of Mayo Clinic’s healthcare system, we understand the best care is provided locally. We complement local expertise by working with clients and logistics organizations to optimize the specimen journey to our laboratories, enabling physicians to get the results they need and patients to remain at home, focused on healing.
Relentless pursuit of answers
Ongoing research propels test development at Mayo Clinic Laboratories, enabling innovative testing that delivers faster, reliable answers to confidently diagnose patients. Our test results not only equip physicians and patients with meaningful diagnostic, prognostic, and therapeutic insights, they also provide hope for a healthier future.
Experience and expertise you can trust
Mayo Clinic Laboratories’ scientists and physicians are leaders in their fields and able to consult on test selection, utilization, and results interpretation. The exchange of knowledge is a founding principle of Mayo Clinic, and we are committed to sharing lessons we’ve learned with our global collaborators through educational opportunities to help improve care delivery in local practices. This is supported through an expansive library of educational content, podcasts, and stories that showcase breakthroughs in test development and perspectives from Mayo Clinic experts.
Access to groundbreaking diagnostics
Driven by an instinct to innovate, we transform scientific discoveries into meaningful advancements in diagnostic testing. Supported by a robust network of Mayo Clinic physicians and scientists and forward-thinking laboratory partners, we foster access to new and advanced testing, much of which is unavailable elsewhere. This integration connects physicians and hospitals around the world with multiple innovative solutions all in one place to support better patient outcomes.
“We treat all of the specimens we receive with the same high degree of care and quality, regardless of where the sample is coming from. We could be testing a sample from a patient that lives in Rochester, Minnesota, or from someone that lives halfway across the world.”
Bobbi Pritt, M.D., Director of the Clinical Parasitology Laboratory
OUR DIFFERENCE
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss a new collaboration and a Mayo Clinic-led study focused on detecting DNA mutations. Later, Dr. Pritt welcomes Andrew McKeon, M.B., B.Ch., M.D., and Anastasia Zekeridou, M.D., Ph.D., co-directors of Mayo Clinic’s Neuroimmunology Laboratory, to discuss how they are advancing patient care.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss a new collaboration and a Mayo Clinic-led study focused on detecting DNA mutations. Later, Dr. Pritt welcomes Andrew McKeon, M.B., B.Ch., M.D., and Anastasia Zekeridou, M.D., Ph.D., co-directors of Mayo Clinic’s Neuroimmunology Laboratory, to discuss how they are advancing patient care.
Register now – Jan. 13, 2027 | Review key 2027 pathology and laboratory CPT code updates, Medicare reimbursement changes, coding resources, and the process for proposing and pricing new codes.
Strategic Lab Collaborations help Mayo Clinic Laboratories accelerate innovation and expand access to advanced diagnostics.
Explore how different types of psychological safety help people move from feeling included to confidently contributing to respectfully challenging ideas.
Due to the Thanksgiving holiday (recognized on Thursday, November 26), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered.
This program reviews urine drug testing for stimulants and phencyclidine (PCP), with an emphasis on the advantages and limitations of traditional immunoassays and targeted mass spectrometry-based screening.
Register now – Dec. 9, 2025 | This webinar will highlight federal and state regulatory updates affecting hospital laboratory outreach programs, including billing, reimbursement, and government enforcement.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss the future of diagnostics. Later, Eric Hsi, M.D., chair of Mayo Clinic’s Department of Laboratory Medicine and Pathology in Rochester, shares how the department is advancing innovation and helping transform healthcare through laboratory medicine.
REGISTER NOW - This presentation examines how autonomous robotic phlebotomy could transform blood collection. It reviews preanalytic challenges, high-opportunity use cases, clinical findings, and Mayo Clinic human-factors research, with a focus on specimen quality, patient acceptance, workflow, workforce models, and human oversight.
A glossary of essential reimbursement terms to help laboratories improve claims, understand coverage, and forecast revenue.
Building on decades of leadership in autoimmune dysautonomia research, Mayo Clinic Laboratories has enhanced its dysautonomia antibody evaluation with a more sensitive, live cell-based flow cytometry method. The streamlined panel focuses on clinically relevant autoantibodies, providing physicians with actionable insights for diagnosis, prognosis, and treatment planning.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Mayo Clinic’s new collaboration with Thermo Fisher and the latest on the Protecting Access to Medicare Act (PAMA). Later, Dr. Pritt welcomes Matt Binnicker, Ph.D., Mayo Clinic Laboratories’ chief scientific officer and a leader in novel diagnostics for viral infections, to explore seasonal virus activity.